Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center and Department of Biostatistics, University of Washington, Seattle, Washington, USA.
J Virol. 2019 Aug 13;93(17). doi: 10.1128/JVI.00629-19. Print 2019 Sep 1.
The RV144 vaccine trial is the only clinical study to have shown a modest but statistically significant decrease in HIV infection risk. RV144 and the subsequent studies identifying the level of V1V2-specific antibodies as a correlate of reduced infection risk are still controversial despite many papers supporting and expanding the initial study. We address these controversies and summarize active-immunization and passive-immunization experiments in nonhuman primates that support the initial finding.
RV144 疫苗试验是唯一一项显示艾滋病毒感染风险适度但具有统计学意义降低的临床研究。尽管有许多论文支持和扩展了最初的研究，但 RV144 以及随后的研究确定 V1V2 特异性抗体水平作为降低感染风险的相关因素仍然存在争议。我们解决了这些争议，并总结了支持最初发现的非人类灵长类动物主动免疫和被动免疫实验。
